Abstract
Inappropriate puberty in the pediatric population is frequently controlled with the use of monthly intramuscular injections of depot GnRH agonist (GnRHa). Currently the gynecologic preparation of GnRHa (intramuscularly every three months) is not indicated by the Food and Drug Administration for the treatment of precocious puberty. There are limited clinical trials determining the efficacy of the three month form in pediatric patients for pubertal suppression.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
